Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| RDHL | 6-K | neutral | 4/10 | RedHill Biopharma announced it is actively discussing potential collaborations to advance its investigational oral drug | Jun 2, 2026 |
| GOSS | 8-K | neutral | 5/10 | Gossamer Bio extended the early tender deadline for its exchange offer to exchange up to $181M of 5.00% Convertible Seni | Jun 2, 2026 |
| MNKD | 8-K | bullish | 7/10 | MannKind announced FDA approval of Afrezza (insulin human) Inhalation Powder for pediatric use in children and adolescen | Jun 2, 2026 |
| BCTXZ | 424B5 | bearish | 6/10 | BriaCell Therapeutics Corp. is offering 1,449,300 common shares at $3.25 per share via a best-efforts placement agent (T | Jun 2, 2026 |
| GLMD | 6-K | neutral | 4/10 | Galmed Pharmaceuticals announced preclinical results from a collaboration with Tissue Dynamics, identifying a previously | Jun 2, 2026 |
| QNTM | 6-K | neutral | 3/10 | Quantum BioPharma engaged Stocks.news/IR Agency LLC for investor relations and marketing services for 6 months at a $250 | Jun 2, 2026 |
| QUCY | PRESS-RELEASE | neutral | 4/10 | Quantum Cyber (QUCY) announced an amendment to its BP United license agreement, taking direct control of drone manufactu | Jun 2, 2026 |
| MDWD | CLUSTER | bullish | 4/10 | Two MediWound directors made open-market purchases totaling $27K over a 4-day window. While the dollar amount is small r | Jun 2, 2026 |
| OPTH | 6-K | neutral | 4/10 | Optimi Health Corp. announced completion of a GMP production run of 5mg psilocybin capsules, the same formulation alread | Jun 2, 2026 |
| LFCR | PRESS-RELEASE | neutral | 4/10 | Lifecore Biomedical announced a manufacturing services agreement with a leading ophthalmic disease management provider f | Jun 2, 2026 |
| RZLT | 8-K | bullish | 7/10 | Rezolute announced positive interim data from its Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism. 6 of 8 enr | Jun 2, 2026 |
| VERA | 8-K | bullish | 7/10 | Vera Therapeutics announced alignment with the FDA on a revised, earlier ORIGIN 3 eGFR analysis plan for atacicept in Ig | Jun 2, 2026 |
| TVTX | 8-K | bullish | 6/10 | Travere Therapeutics entered into a license and collaboration agreement with EverestMedicines for exclusive rights to de | Jun 2, 2026 |
| CANF | 6-K | neutral | 4/10 | Can-Fite BioPharma issued a press release highlighting positive clinical observations from its Phase 2a pancreatic cance | Jun 2, 2026 |
| TLX | PRESS-RELEASE | neutral | 4/10 | Telix Pharmaceuticals and United Imaging signed an MOU to evaluate a strategic research collaboration integrating Telix' | Jun 2, 2026 |
| VERA | PRESS-RELEASE | bullish | 7/10 | Vera Therapeutics announced FDA alignment on a revised, earlier eGFR analysis plan for atacicept in IgA Nephropathy, pul | Jun 2, 2026 |
| BYSI | PRESS-RELEASE | bullish | 7/10 | BeyondSpring presented updated Phase 2 data at ASCO 2026 for its triple combination (pembrolizumab + Plinabulin + doceta | Jun 2, 2026 |
| TRDA | PRESS-RELEASE | neutral | 4/10 | Entrada Therapeutics announced that an independent DMC recommended dose escalation to 10 mg/kg in Cohort 2 of the ELEVAT | Jun 2, 2026 |
| KRRO | CLUSTER | neutral | 3/10 | Two insiders at Korro Bio, CEO Ram Aiyar and Director Jean Francois Formela, sold a combined $231K in open-market sales | Jun 2, 2026 |
| CASIF | 6-K | neutral | 2/10 | CASI Pharmaceuticals disclosed the resignation of director Dr. Barbara Krebs-Pohl, effective May 31, 2026, with no disag | Jun 2, 2026 |
| GYRE | 8-K | neutral | 4/10 | Gyre Therapeutics filed an 8-K furnishing an updated corporate investor presentation. The presentation highlights the co | Jun 2, 2026 |
| OTLK | CLUSTER | mixed | 6/10 | A cluster of insider purchases totaling ~$5.24M occurred at Outlook Therapeutics over the past week, dominated by a $5.0 | Jun 1, 2026 |
| QTTB | CLUSTER | bullish | 8/10 | Directors OrbiMed Advisors and Xu Diyong each purchased $10M of QTTB common stock at $8/share on May 28, 2026, for a tot | Jun 1, 2026 |
| EVMN | CLUSTER | neutral | 3/10 | CFO and Chief Business & Legal Officer sold a combined $740K in open-market sales on May 28, 2026, following derivative | Jun 1, 2026 |
| ALKS | CLUSTER | neutral | 2/10 | Two Alkermes insiders, the Chief Medical Officer and the Interim Principal Accounting Officer, sold a combined $1.06M in | Jun 1, 2026 |
| CYTK | CLUSTER | neutral | 3/10 | Two insiders at Cytokinetics, including the President & CEO, sold a total of $949K in open-market sales over a one-week | Jun 1, 2026 |
| OKYO | 3 | neutral | 2/10 | Form 3 filing by director Simon Willy Jules discloses initial beneficial ownership in OKYO Pharma Ltd, including 6,435 s | Jun 1, 2026 |
| OKYO | 3 | neutral | 2/10 | John P. Brancaccio filed a Form 3 initial statement of beneficial ownership with the SEC, disclosing his holdings in OKY | Jun 1, 2026 |
| ANAB | 144 | bearish | 5/10 | Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 on June 1, 2026, indicating intent to sell 7,691 shares of com | Jun 1, 2026 |
| CSTL | 144 | neutral | 4/10 | CEO Derek Maetzold filed a Form 144 on June 1, 2026, to sell 14,008 shares of Castle Biosciences common stock, with an e | Jun 1, 2026 |